D.E. Shaw & Co
CRVS icon

D.E. Shaw & Co’s Corvus Pharmaceuticals CRVS Stock Holding History

D.E. Shaw & Co’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
+133,177
New +$1.85M ﹤0.01% 3215
2026
Q1 		– Sell
-64,915
Closed -$500K – 4625
2025
Q4 		$500K Buy
64,915
+39,340
+154% +$310K ﹤0.01% 3930
2025
Q3 		$188K Buy
+25,575
New +$131K ﹤0.01% 4296

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

D.E. Shaw & Co's CRVS Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 133,177 shares worth $1.99M. The stake represents ﹤0.01% of the portfolio and ranks #3215 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in CRVS as recently as Q4 2025.

D.E. Shaw & Co first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • D.E. Shaw & Co held 133,177 shares of Corvus Pharmaceuticals worth $1.99M as of Q2 2026.
  • Corvus Pharmaceuticals was a new D.E. Shaw & Co position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3215 holding.
  • D.E. Shaw & Co first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.